TY  - JOUR
AU  - Blancas, I
AU  - Olier, C
AU  - Conde, V
AU  - Bayo, J L
AU  - Herrero, C
AU  - Zarcos-Pedrinaci, I
AU  - Carabantes, F
AU  - Baena-Cañada, J M
AU  - Cruz, J
AU  - Ruiz-Borrego, M
PY  - 2021
DO  - 10.1038/s41598-021-83622-1
UR  - http://hdl.handle.net/10668/17201
T2  - Scientific reports
AB  - Goals of endocrine therapy for advanced breast cancer (ABC) include prolonging survival rates, maintaining the quality of life, and delaying the initiation of chemotherapy. We evaluated the effectiveness of fulvestrant as first-line in patients with...
LA  - en
PB  - Nature Publishing Group
KW  - Antineoplastic agents, hormonal
KW  - Biomarkers, tumor
KW  - Breast neoplasms
KW  - Estrogen receptor antagonists
KW  - Aged
KW  - Antineoplastic agents, hormonal
KW  - Biomarkers, tumor
KW  - Breast neoplasms
KW  - Estrogen receptor antagonists
KW  - Female
KW  - Fulvestrant
KW  - Humans
KW  - Middle aged
KW  - Neoplasm staging
KW  - Postmenopause
KW  - Prognosis
KW  - Receptors, estrogen
KW  - Retrospective studies
KW  - Treatment outcome
TI  - Real-world data of fulvestrant as first-line treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer.
TY  - research article
VL  - 11
ER  -